VXRT Vaxart

Vaxart Announces Positive Hamster Challenge Study Data for its Oral COVID-19 Vaccine

Vaxart Announces Positive Hamster Challenge Study Data for its Oral COVID-19 Vaccine
EN
14/10/2020

Underlying

VXRTVaxart

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Vaxart

 PRESS RELEASE
Free
VXRT VAXART

Vaxart to Present at the Oppenheimer 36th Annual Healthcare Life Scien...

Vaxart to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026 SOUTH SAN FRANCISCO, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral vaccines based on its proprietary delivery platform, today announced that members of the management team will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference taking place virtually February 25-26, 2026. Presentation Details: Date and Time: Wednesday, February 25 at 4:00pm ETRegistration and Webcast: ...

17h / 10m 1 EN
 PRESS RELEASE
Free
VXRT VAXART

Vaxart Publishes Positive Data for its Oral Bivalent Norovirus Candida...

Vaxart Publishes Positive Data for its Oral Bivalent Norovirus Candidate in Lactating Women and Their Infants Vaccine was safe and well-tolerated and led to a significant increase in norovirus-specific antibodies in serum and breast milk Norovirus-specific IgA in infant stool correlated with breast milk IgA, suggesting passive transfer of immunity to breastfed infants and the potential for a new approach to confer mucosal anti-norovirus immunity to a vulnerable population SOUTH SAN FRANCISCO, Calif., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”...

January 15, 2026 1 EN
 PRESS RELEASE
Free
VXRT VAXART

Vaxart to Participate in the Global BioInnovation Forum on January 13,...

Vaxart to Participate in the Global BioInnovation Forum on January 13, 2026 SOUTH SAN FRANCISCO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart or “the Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced that it will participate in the Global BioInnovation Forum, a virtual gathering of senior leaders building and scaling next-generation life science and health innovation companies. Presentation Details: Speakers: Steven Lo, Chief Executive Officer, Sean T...

January 8, 2026 1 EN
 PRESS RELEASE
Free
VXRT VAXART

Vaxart Provides Business Update and Reports Third Quarter 2025 Financi...

Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results Entered into an exclusive license agreement with Dynavax for the Company’s COVID-19 oral pill vaccine candidate for potential cumulative proceeds of up to $700 million plus royalties Completed enrollment of approximately 5,400 participants in COVID-19 Phase 2b trial with topline data expected in late 2026; Topline data from 400-person sentinel cohort anticipated in the first quarter of 2026 Reported additional supportive data from Phase 1 clinical trial evaluating Company’s second-generation oral norovirus va...

November 13, 2025 1 EN
 PRESS RELEASE
Free
VXRT VAXART

Vaxart to Host Upcoming Conference Calls

Vaxart to Host Upcoming Conference Calls Third quarter 2025 results conference call to be held on November 13 at 4:30 p.m. ET Stockholder fireside chat to be held on November 18 at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart”) today announced it will host two upcoming webcast conference calls. Third Quarter 2025 Financial ResultsVaxart will provide a business update and report financial results for the third quarter ended September 30, 2025, after the market close on Thursday, November 13, 2025. The Vaxart senior mana...

November 7, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch